Hypomethylating agent as first-line treatment for acute myeloid leukemia: Systematic review

被引：0
|
作者：
Jhoputri, Caroline Fricilia [1 ]
Tandokallo, Felicia [1 ]
Kosayuz, Sherina [1 ]
Atmaja, William Surya [1 ]
Kurniawan, Andree [2 ]
机构：
[1] Pelita Harapan Univ, Fac Med, Tangerang, Indonesia
[2] Pelita Harapan Univ, Dept Internal Med, Fac Med, Tangerang, Indonesia
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.343
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P12-2
引用
收藏
页码：S1446 / S1446
页数：1
相关论文
共 50 条
  • [1] Hypomethylating agents as first-line therapy in acute myeloid leukemia (AML).
    Bailey, Samuel D.
    Gul, Zartash
    Slone, Stacey A.
    Van Meter, Emily Marie
    Lawson, Amber
    Raufi, Ali
    Hayslip, John W.
    Monohan, Gregory
    Howard, Dianna S.
    McDonagh, Kevin T.
    Alkadhimi, Zaid
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [2] Venetoclax with decitabine or azacitidine in the first-line treatment of acute myeloid leukemia
    Bouligny, Ian M.
    Murray, Graeme
    Doyel, Michael
    Patel, Tilak
    Boron, Josh
    Tran, Valerie
    Gor, Juhi
    Hang, Yiwei
    Alnimer, Yanal
    Zacholski, Kyle
    Venn, Chad
    Wages, Nolan A.
    Grant, Steven
    Maher, Keri R.
    EJHAEM, 2023, 4 (02): : 381 - 392
  • [3] Hypomethylating agent for acute myeloid leukemia, the efficacy and its effect towards mortality rate: Systematic review
    Tandokallo, Felicia
    Jhoputri, Caroline Fricilia
    Kosayuz, Sherina
    Atmaja, William Surya
    Kurniawan, Andree
    ANNALS OF ONCOLOGY, 2023, 34 : S1446 - S1446
  • [4] PHARMACOECONOMIC EVALUATION OF NILOTINIB VERSUS IMATINIB IN THE FIRST-LINE TREATMENT OF CHRONIC MYELOID LEUKEMIA: A SYSTEMATIC REVIEW
    Nguyen, T. T.
    Nguyen, T. T.
    Nguyen, T. B.
    VALUE IN HEALTH, 2017, 20 (05) : A111 - A111
  • [5] Asciminib treatment in first-line chronic myeloid leukemia
    Chanut, Mathilde
    HEMATOLOGIE, 2024, 30 (06):
  • [6] Therapeutic Advances in First-Line Management of Acute Myeloid Leukemia
    Pollyea, Daniel A.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2019, 17 (11): : 1441 - 1443
  • [7] Adding venetoclax or hypomethylating agents to induction chemotherapy as first-line treatment for adults with acute myeloid leukemia: a retrospective case-cohort study
    Xu, Fangfei
    Zhou, Kuangguo
    Gong, Duanhao
    Huang, Wei
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2024, 15
  • [8] Decitabine as a First-Line Treatment for Older Adults Newly Diagnosed with Acute Myeloid Leukemia
    Park, Hyunsung
    Chung, Haerim
    Lee, Jungyeon
    Jang, Jieun
    Kim, Yundeok
    Kim, Soo Jeong
    Kim, Jin Seok
    Min, Yoo Hong
    Cheong, June-Won
    YONSEI MEDICAL JOURNAL, 2017, 58 (01) : 35 - 42
  • [9] Use of Arsenic Trioxide As a First-Line Single Agent in the Treatment of Acute Promyelocytic Leukemia
    Keyhani, Manoutchehr
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (02) : 217 - 217
  • [10] Heterogeneous Definitions of Secondary Acute Myeloid Leukemia (AML) Yield Distinct Outcomes in Response to First-Line Treatment with Hypomethylating Agents (HMA) and Venetoclax (Ven)
    Tan, Irena
    Schwede, Matthew
    Phan, Paul
    Yin, Raymond
    Zhang, Tian Y.
    Mannis, Gabriel N.
    BLOOD, 2021, 138
12345